Showing results (41-50 of 302) with videos related to

Sort By:
Pageof 31
Oncotarget|December 15, 2015
Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphomaAloke Sarkar, Kumudha Balakrishnan, Jefferson Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2016
Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell LymphomaQingshan Yang, Lisa S Chen, Min Jin Ha, et al.
Haematologica|October 12, 2019
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphomaPaolo Strati, Mohamed Amin Ahmed, Nathan H Fowler, et al.
British Journal of Haematology|January 12, 2026
Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphomaKunhwa Kim, Rahul Shah, Amy Ayers, et al.
Leukemia & Lymphoma|August 26, 2021
A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphomaHua-Jay J Cherng, Hubert H Chuang, Raphael Steiner, et al.
Mayo Clinic Proceedings|May 6, 2018
Chronic Lymphocytic Leukemia: Diagnosis and TreatmentPaolo Strati, Nitin Jain, Susan O'Brien
American Journal of Clinical Oncology|May 29, 2019
Clinical Features of Rituximab-associated Gastrointestinal ToxicitiesNiharika Mallepally, Hamzah Abu-Sbeih, Osman Ahmed, et al.
Expert Review of Vaccines|July 11, 2006
Therapeutic lymphoma vaccines: importance of T-cell immunitySattva S Neelapu, Seung-Tae Lee, Hong Qin, et al.
Blood|June 1, 2012
Essential role of TAK1 in regulating mantle cell lymphoma survivalDaniela Buglio, Sangeetha Palakurthi, Kate Byth, et al.
Blood|September 15, 2009
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunityHong Qin, Soung-chul Cha, Sattva S Neelapu, et al.
Pageof 31